Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Principal Technologies's Debt-to-EBITDA or its related term are showing as below:
FRA:JO7'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.22 Med: -0.07 Max: -0.05
Current: -0.22
During the past 6 years, the highest Debt-to-EBITDA Ratio of Principal Technologies was -0.05. The lowest was -0.22. And the median was -0.07.
FRA:JO7's Debt-to-EBITDA is ranked worse than 100% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.21
vs FRA:JO7: -0.22
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Principal Technologies Debt-to-EBITDA Related Terms
Principal Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Principal Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:JO7 vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Principal Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Principal Technologies Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Principal Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Principal Technologies (FRA:JO7) has a Debt-to-EBITDA of -0.28 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Principal Technologies. According to the industry distribution chart, Principal Technologies ranks #999999 out of 476 companies in the Healthcare Providers & Services industry.
Is Principal Technologies' Debt-to-EBITDA too high?
Principal Technologies' current Debt-to-EBITDA is -0.28. Based on the distribution chart, Principal Technologies ranks #999999 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Principal Technologies has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Principal Technologies' Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Principal Technologies ranks #999999 out of 476 companies for Debt-to-EBITDA. This places Principal Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Principal Technologies. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Principal Technologies's current Debt-to-EBITDA is -0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Principal Technologies stock overvalued right now?
Based on GuruFocus' analysis, Principal Technologies (FRA:JO7) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.24 — trading 490% above its estimated fair value. The current Debt-to-EBITDA is -0.28. Principal Technologies' overall GF Score™ is 12/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Principal Technologies (FRA:JO7), the current Debt-to-EBITDA is -0.28 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Principal Technologies (FRA:JO7) Overvalued in 2026?
Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued.
The current stock price of €0.24 is trading 490% above its estimated GF Value™ of €0.04.
GuruFocus considers Principal Technologies to be Significantly Overvalued.
Key valuation signals for FRA:JO7:
Debt-to-EBITDA: -0.28
GF Value™: €0.04 vs. price of €0.24 (490% above fair value)
No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
12GF Score
Get the complete analysis for FRA:JO7
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JO7 has been successfully added to your 
